These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16432973)

  • 1. Dyslipidemia and the risk of end stage renal disease.
    Haydar AA; Goldsmith DJ
    J Med Liban; 2004; 52(3):156-9. PubMed ID: 16432973
    [No Abstract]   [Full Text] [Related]  

  • 2. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Statins in chronic renal disease].
    Ferreira SR; Rocha AM; Saraiva JF
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():45-9. PubMed ID: 16400399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
    Montague T; Murphy B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
    Watanabe T
    Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins in patients with chronic kidney disease: a double-edged sword?
    Kassimatis TI; Konstantinopoulos PA
    J Am Coll Cardiol; 2008 Nov; 52(20):1679; author reply 1680. PubMed ID: 18992660
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. At which stage of chronic kidney disease should dyslipidemia be treated?
    Krane V; Wanner C
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):176-7. PubMed ID: 16932418
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical practice guidelines for the management of dyslipidemia in chronic kidney disease].
    Shoji T
    Nihon Jinzo Gakkai Shi; 2013; 55(7):1267-75. PubMed ID: 24288962
    [No Abstract]   [Full Text] [Related]  

  • 11. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cardiovascular disease in chronic kidney disease patients.
    Wanner C
    Semin Nephrol; 2009 Jan; 29(1):24-9. PubMed ID: 19121471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of statins on renal function.
    Agarwal R
    Am J Cardiol; 2006 Mar; 97(5):748-55. PubMed ID: 16490450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of lipid abnormalities associated with end-stage renal disease.
    Liu J; Kalantarinia K; Rosner MH
    Semin Dial; 2006; 19(5):391-401. PubMed ID: 16970739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statins: what is their place in the treatment of chronic kidney insufficiency?].
    Ponte B; Bourquin V; Stoermann-Chopard C
    Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria as a therapeutic target in patients with chronic kidney disease.
    Palmer BF
    Am J Nephrol; 2007; 27(3):287-93. PubMed ID: 17457028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and secondary prevention of heart failure with statins.
    Udell JA; Ray JG
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):917-26. PubMed ID: 17173505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of dyslipidemia in renal disease and transplantation.
    Zolezzi M
    Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):129-36. PubMed ID: 16903617
    [No Abstract]   [Full Text] [Related]  

  • 19. HMG-CoA reductase inhibitors and the kidney.
    Campese VM; Park J
    Kidney Int; 2007 Jun; 71(12):1215-22. PubMed ID: 17495867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.